Scientific publications
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Scientific Publication
Maria-Victoria Mateos # 1 , Katja Weisel # 2 , Valerio De Stefano 3 , Hartmut Goldschmidt 4 , Michel Delforge 5 , Mohamad Mohty 6 , Michele Cavo 7 , Ravi Vij 8 , Joanne Lindsey-Hill 9 , Dominik Dytfeld 10 , Emanuele Angelucci 11 , Aurore Perrot 12 , Reuben Benjamin 13 , Niels W C J van de Donk 14 , Enrique M Ocio 15 , Christof Scheid 16 , Francesca Gay 17 , Wilfried Roeloffzen 18 , Paula Rodriguez-Otero 19 , Annemiek Broijl 20 , Anna Potamianou 21 , Caline Sakabedoyan 22 , Maria Semerjian 23 , Sofia Keim 24 , Vadim Strulev 25 , Jordan M Schecter 26 , Martin Vogel 27 , Robert Wapenaar 28 , Tonia Nesheiwat 29 , Jesus San-Miguel 19 , Pieter Sonneveld 20 , Hermann Einsele 30 , Philippe Moreau 31
Abstract
Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs).
LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life standard of care (SOC) in triple-class exposed (received at least a PI, IMiD, and anti-CD38 mAb) patients with relapsed/refractory MM (RRMM).
Patients (N = 248; ECOG performance status of 0-1, ≥3 prior lines of therapy or double refractory to a PI and IMiD) were treated with median 4.0 (range, 1-20) cycles of SOC therapy. Overall response rate was 29.8% (95% CI: 24.2-36.0). Median progression-free survival (PFS) and median overall survival (OS) were 4.6 (95% CI: 3.9-5.6) and 12.4 months (95% CI: 10.3-NE).
Treatment-emergent adverse events (TEAEs) were reported in 83.5% of patients (52.8% grade 3/4). Altogether, 107 deaths occurred, due to progressive disease (n = 74), TEAEs (n = 19), and other reasons (n = 14). The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action.
CITATION Leukemia. 2022 May;36(5):1371-1376. doi: 10.1038/s41375-022-01531-2. Epub 2022 Mar 24
Our authors
